Breathe Well: Improving Cancer Imaging And Targeted Radiotherapy Using Audiovisual Biofeedback
Funder
National Health and Medical Research Council
Funding Amount
$606,847.00
Summary
Irregular breathing causes anatomical errors in medical images and consequently cancer targeting accuracy, resulting in poorer clinical outcomes and increased health care costs. We have developed and patented the Breathe Well Audio Visual (AV) biofeedback device, to improve breathing regularity. Our goal is to gather critical scientific information and reach commercial proof-of-concept objectives that will allow us to attract investment to establish a viable medical device enterprise.
Radiotherapy Treatment For Prostate Cancer - A Change In Practice Based On Direct Evidence For Targeting And Toxicity Effects Using Real Outcomes Data
Funder
National Health and Medical Research Council
Funding Amount
$555,129.00
Summary
Radiotherapy for prostate cancer treatment will be more effective when we have better knowledge of what patient anatomy needs to be targeted, and what needs to be avoided. This project will combine data collected during a large Australasian prostate cancer radiotherapy trial, ‘RADAR’, with data collected using new patient imaging methods to determine how patient anatomy impacts on the effectiveness of their treatment and the side-effects they experience.
Heparin-induced Thrombocytopenia And Thrombosis: Better Understanding Of Pathogenesis And Improving Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$653,137.00
Summary
Heparin, a widely used drug, can cause an adverse effect which results in a fall of the platelet count and the development of serious thrombosis. This drug complication is mediated by an immune mechanism. This proposal aims to provide a better understanding of the disease mechanism. It also aims to develop a new test that will improve the diagnosis, and to produce a novel drug that will effectively suppress the immune reaction and improve the treatment.
Development Of A New High Throughput Screen For Drug Binding To HERG K+ Channels
Funder
National Health and Medical Research Council
Funding Amount
$351,320.00
Summary
Inadvertent drug block of hERG, a potassium channel in the heart, can cause cardiac arrhythmias and sudden cardiac death. Screening for hERG toxicity has become a major hurdle for development of new drugs. We will use a mutant hERG protein that has enhanced drug binding to develop a high throughput test for hERG toxicity. Identification of dangerous drugs early in the drug discovery process will save the pharmaceutical industry millions of dollars in the costs of brining new drugs to market.
Through this Australia Fellowship, Prof Keall and his tream will substantially improve the accuracy and effectiveness of radiation therapy for cancer by developing new techniques that will be able to ‘target’ a tumour in real-time and ‘concentrate fire’ on the most resistant and aggressive parts of it. Success in physiological targeting will create a paradigm shift in radiation therapy and could literally be a lifesaver. It’s a big challenge, but if this five-year research program succeeds, it w ....Through this Australia Fellowship, Prof Keall and his tream will substantially improve the accuracy and effectiveness of radiation therapy for cancer by developing new techniques that will be able to ‘target’ a tumour in real-time and ‘concentrate fire’ on the most resistant and aggressive parts of it. Success in physiological targeting will create a paradigm shift in radiation therapy and could literally be a lifesaver. It’s a big challenge, but if this five-year research program succeeds, it will pay big dividendsRead moreRead less
Drug-induced Immune Thrombocytopenia: Understanding The Disease Mechanisms Is The Key To Better Treatment
Funder
National Health and Medical Research Council
Funding Amount
$509,550.00
Summary
Many very commonly used medications cause an allergic reaction in a small number of patients that receive them. The allergic reaction results in platelets being destroyed and puts the patients at risk of bleeding. The patient recovers slowly if the drug is stopped but there is no other treatment and no way to reverse the effect quickly if the patient starts to bleed. This project will try to understand the mechanism of the condition and test a potential treatment.
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.
Optimising Radiation Therapy Delivery For Cancer Patients Using Daily Image Guidance To Maximize Cure And Reduce Normal Tissue Side Effects
Funder
National Health and Medical Research Council
Funding Amount
$510,968.00
Summary
When using radiotherapy to kill tumours, the radiation beams need to be targeted at the tumour, plus a margin of error around it to ensure that it receives sufficient dose despite uncertainties in its exact location relative to reference points used for beam alignment. Advanced statistical modelling techniques applied to data collected from patients will be used to determine the optimal margin width for individual patients to maximise cancer cure while minimising normal tissue side effects.
Investigation Of A New Electronic Portal Imaging Device For Radiation Therapy Dose Delivery Verification
Funder
National Health and Medical Research Council
Funding Amount
$408,101.00
Summary
In external beam radiotherapy highly complex radiation fields are used to deliver high doses of radiation to the tumour while sparing normal tissues. Inaccurate treatment could result in poor patient outcome or damage to normal tissues. We aim to investigate a novel imaging device to measure the dose accuracy of these fields. This work has the potential to make a significant and fundamental difference to existing verification techniques for radiotherapy treatments to ensure patient outcomes.